Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Chemed Results Top Estimates; Outlook Strong

RELATED NEWS
Trade CHE now with 

Chemed Corp. (CHE: Quote) said Monday that its fourth quarter profit rose 4% from last year, as strong performance by its VITAS segment more than offset the weakness in its Roto-Rooter segment.

The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a strong earnings outlook for the current year.

Chemed operates VITAS Healthcare Corp., the largest U.S. provider of end-of-life care, and Roto-Rooter, the largest commercial and residential plumbing and drain cleaning services provider in the U.S.

Fourth quarter revenue for the VITAS segment rose 7.2% to $273 million, due to a 5.4% increase in Average Daily Census.

Roto-Rooter's plumbing and drain cleaning business generated fourth quarter revenue of $95.6 million, a decrease of 0.1% from a year earlier.

For the fourth quarter ended December 31, 2012, Chemed reported net income of $26.7 million or $1.40 per share, compared to $25.7 million or $1.31 per share for the year-ago quarter.

Excluding items, adjusted net income for the fourth quarter was $29.9 million or $1.57 per share, compared to $28.3 million or $1.45 per share in the prior year quarter.

On average, 5 analysts polled by Thomson Reuters expected the company toe earn $1.48 per share for the fourth quarter. Analysts' estimates typically exclude special items.

Chemed's total revenue for the fourth quarter rose 5.2% to $368.58 million from $350.25 million in the same quarter last year. Four analysts had a consensus revenue estimate of $364.95 million for the fourth quarter.

Looking forward, Chemed forecast 2013 adjusted earnings of $5.65 to $5.80 per share. Analysts currently expect the company to earn $5.47 per share for the full year 2013.

Chemed shares closed Friday's regular trading session at $76.09, down 71 cents.

Register
To receive FREE breaking news email alerts for Chemed Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.